The impact of emotional dysregulation and comorbid depressive symptoms on clinical features, brain arousal, and treatment response in adults with ADHD.

Introduction: The role of emotional dysregulation (ED) in attention-deficit/hyperactivity disorder (ADHD) has become an important issue. This study, in which we analyzed data from a predictive pharmaco-EEG-trial, aimed to examine whether symptoms of ED in adult ADHD affect ADHD symptom severity, brain arousal regulation as measured by resting EEG, and the response to stimulant medication.
Methods: ED is defined as having a sex- and age-corrected T -score of >70 on the emotional lability subscale of the German version of Conners' Adult ADHD Rating Scale. A total of 115 participants were included in the study, 56 of whom had ED. Participants with ED were more impaired in terms of the severity of core ADHD symptoms, especially inattentive symptoms, comorbid depressive symptoms, interpersonal relationships, and quality of life. In addition, participants with ED were more likely to report a total score above 13 on the Beck Depression Inventory-II, which was considered to be the cutoff for mild depression.
Results: No differences were found between the ED and non-ED groups in response to stimulant medication or in brain arousal regulation. In addition, there was no significant effect of ED with comorbid depressive symptoms on treatment response. There was a trend for subgroups that showed a change in brain arousal regulation associated with symptom improvement.
Discussion: Our findings may support the assumption that ED may be an important feature of ADHD. The use of EEG-based brain arousal regulation as a diagnostic and predictive tool in ADHD in the presence of ED and comorbid depressive symptoms should be further investigated.
Competing Interests: MS has received speaker’s fees from MEDICE Arzneimittel Pütter GmbH & Co. KG and Takeda and was an advisory board member for Takeda in the past 3 years. AR has received honoraria for advisory boards or talks from MEDICE Arzneimittel Pütter GmbH & Co. KG, Takeda, Janssen, Boehringer Ingelheim, SAGE/Biogen, cyclerion, COMPASS and LivaNova. JG has received research funding from the German Federal Ministry of Education and Research, German Science Foundation, and speaker fees from Lundbeck, Janssen-Cilag, Lilly, and Boehringer. SK-S. has received author’s and speaker’s honoraria from Takeda and Medice Arzneimittel Pütter GmbH &Co. KG in the past 3 years. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Huang, Mauche, Ahlers, Bogatsch, Böhme, Ethofer, Fallgatter, Gallinat, Hegerl, Heuser, Hoffmann, Kittel-Schneider, Reif, Schöttle, Unterecker and Strauß.)